Dermatitis Atopic
Conditions
Brief summary
This is a Phase 2, multicenter, randomized, double-blind placebo controlled, 2-arm study to evaluate the effect of amlitelimab on vaccine antibody responses, and the safety of amlitelimab concurrently administered with non-live vaccines in adult participants with moderate-to-severe atopic dermatitis (AD). The purpose of this study is to compare the immune responses to concomitantly administered Boostrix (tetanus, diphtheria, and acellular pertussis \[Tdap\]) and Pneumovax 23 (PPSV) vaccines in adult participants with moderate-to-severe AD treated with amlitelimab versus placebo. The study will evaluate the percentage of participants achieving a positive anti-tetanus response at Week 16 (primary endpoint) and a positive anti-pneumococcal response at Week 16 (key secondary endpoint). Study details include: The study duration will be up to 36 weeks (for participants not entering the LTS17367 \[RIVER-AD\]). The screening period will be 9 days to 4 weeks. The treatment duration will be up to 16 weeks. The post-treatment safety follow-up period will be16 weeks. The number of visits will be up to 7 (or 6 for those entering LTS17367 \[RIVER-AD\]).
Detailed description
The study duration will be up to 36 weeks
Interventions
DRUGAmlitelimab
Subcutaneous injection in abdomen, outer thigh, or upper arm
DRUGPlacebo
Subcutaneous injection in abdomen, outer thigh, or upper arm
BIOLOGICALTdap vaccine
Intramuscular (IM) injection into the deltoid muscle of the upper arm
BIOLOGICALPPS vaccine
Intramuscular or subcutaneous injection into the deltoid muscle of the upper arm
Sponsors
Sanofi
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Participants must be 18 years of age (when signing informed consent form) * Diagnosis of AD for at least 1 year (defined by the American Academy of Dermatology Consensus Criteria) * Documented history (within 6 months before screening) of either inadequate response or inadvisability to topical treatments * Validated Investigator Global Assessment scale for atopic dermatitis (vIGA-AD) of 3 or 4 at baseline visit * Eczema area and severity index (EASI) score of 12 or higher at baseline * AD involvement of 10% or more of body surface area (BSA) at baseline * Able and willing to comply with requested study visits and procedures * Body weight ≥40 kg and ≤150 kg
Exclusion criteria
* Skin co-morbidity that would adversely affect the ability to undertake AD assessments * Receipt of any vaccine (expect influenza and COVID-19 vaccines) within 3 months prior to screening * Receipt of any pneumococcal vaccine within approximate timeframe of 5 years prior to screening * Prior receipt of two or more doses of Pneumovax 23 at any time * Receipt of any tetanus-, diphtheria-, or pertussis-containing vaccine within approximate timeframe of 5 years prior to screening * Participants for whom administration of the pneumococcal vaccine provided in this study is contraindicated or medically inadvisable, according to local label of the vaccine * Participants for whom administration of the tetanus, diphtheria, and pertussis vaccine provided in this study is contraindicated or medically inadvisable, according to local label of the vaccine * Having received any of the specified therapy within the specified timeframe(s) prior to the baseline visit * Known history of or suspected significant current immunosuppression * Any malignancies or history of malignancies prior to baseline (excluding non-melanoma skin cancer excised and cured \>5 years prior to baseline) * History of solid organ or stem cell transplant * Any active or chronic infection including helminthic infection requiring systemic treatment within 2 weeks prior baseline * Positive for human immunodeficiency virus (HIV), Hepatitis B or hepatitis C at screening visit * Participants with active tuberculosis (TB), latent TB, a history of incompletely treated TB, suspected extrapulmonary TB infection, or who are at high risk of contracting TB The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of participants with a positive tetanus response at Week 16 | Week 16 | Positive tetanus response is defined as ≥2.5 IU/mL in anti-tetanus immunoglobulin G \[IgG\] titer for participants with a pre-vaccination baseline \[Week 12\] tetanus antibody titer of \>1 IU/mL or a titer ≥ 3-fold increase for participants with a pre-vaccination titer of ≤1IU/mL). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of participants with a positive pneumococcal vaccine response at Week 16 | Week 16 | Positive pneumococcal vaccine response is defined as a ≥2-fold increase from baseline in anti-pneumococcal antibodies (APAb) against \>50% of the 23 serotypes. |
| Percentage of participants who experienced treatment-emergent adverse events (TEAE), including serious adverse events (SAE) and adverse events of special interest (AESI) | Week 0 up to Week 32 | — |
| Percentage of participants with potentially clinically significant abnormalities (PCSA) for vital signs and clinical laboratory assessments | Week 0 up to Week 32 | — |
| Percentage of participants discontinued from study treatment due to TEAEs | Week 0 up to Week 32 | — |
| Proportion of participants with validated Investigator Global Assessment scale for atopic dermatitis (vIGA-AD) of 0 (clear) or 1 (almost clear) and a reduction of ≥2 points from baseline at Week 16 | Week 16 | The vIGA-AD is an Investigator-completed assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale, ranging from 0 (clear) to 4 (severe). |
| Proportion of participants with a ≥75% reduction in EASI score (EASI-75) from baseline at Week 16 | Week 16 | The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD using a 4-point scale; 0 (absent) to 3 (severe). |
| Serum amlitelimab concentrations | Week 0 up to Week 16 | — |
| Incidence of antidrug antibodies (ADAs) of amlitelimab | Week 0 up to Week 16 | — |
Countries
Canada, United States
Contacts
STUDY_DIRECTORClinical Sciences & Operations
Sanofi
Outcome results
None listed